In situ quantification of aberrant p53 in colorectal neoplasia

Steven Jay Smith, Alfred Neugut, Daniel Heitjan, Kenneth Forde, Peter Holt, Regina M. Santella, Luo Jiin-Chyuan, Walter Carney, Llewelyn Ward, Paul W. Brandt-Rauf

Research output: Contribution to journalArticle

Abstract

Aberrant p53 protein accumulation was measured immunohistologically in 342 colorectal paraffin-embedded tissue sections from 115 patients (24 with adenocarcinoma, 59 with adenoma and 32 'hospital controls'). Subjective scoring was compared with quantitative cell imaging, including dichotomous (p53+/p53-) status, ng p53mut mg-1 enterocyte protein, and tumour burden and patient body 'burden' of aberrant p53. A total of 62.5% cancer patients, 23.7% adenoma patients and 3.1% hospital controls were accorded p53+ status on the basis of p53 quantification. Quantitative p53+/p53- assignment had a stronger inverse association with survival (χ2 = 6.17, p = 0.013, Kaplan-Meier test) than subjective 'visual estimation' (χ2 = 0.57, p = 0.449). There was a strong inverse relationship between the p53 'body burden' and the months of post-diagnosis survival (hazard ratio = 1.42, p = 0.0004, Cox proportional hazards). Absolute quantification for inactivated p53 permits objective and reproducible scoring, adjusts for intra-laboratory immunostaining 'batch effects', corrects for fixation artefacts, and standardizes for inter-laboratory differences in fixation, antibody selection and staining method. Clinically, in situ quantification of p53 will permit more accurate survival prognoses and will inform therapy selection and dose. Ultimately, accurate quantitative tissue/blood p53 correlations may provide a minimally invasive and systemic surrogate measure for these same clinical purposes.

Original languageEnglish (US)
Pages (from-to)311-332
Number of pages22
JournalBiomarkers
Volume8
Issue number4/3
DOIs
StatePublished - May 1 2003

Fingerprint

Hazards
Tissue
Body Burden
Adenoma
Paraffin
Survival
Tumors
Neoplasms
Proteins
Blood
Imaging techniques
Antibodies
Enterocytes
Kaplan-Meier Estimate
Tumor Burden
Artifacts
Adenocarcinoma
Staining and Labeling
Therapeutics

Keywords

  • Cell imaging densitometry
  • Colorectal
  • Immunohistochemistry
  • p53
  • Protein quantitation
  • Tumour/tumour tissue

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Cite this

Smith, S. J., Neugut, A., Heitjan, D., Forde, K., Holt, P., Santella, R. M., ... Brandt-Rauf, P. W. (2003). In situ quantification of aberrant p53 in colorectal neoplasia. Biomarkers, 8 (4/3), 311-332. https://doi.org/10.1080/1354750031000138676

In situ quantification of aberrant p53 in colorectal neoplasia. / Smith, Steven Jay; Neugut, Alfred; Heitjan, Daniel; Forde, Kenneth; Holt, Peter; Santella, Regina M.; Jiin-Chyuan, Luo; Carney, Walter; Ward, Llewelyn; Brandt-Rauf, Paul W.

In: Biomarkers, Vol. 8 , No. 4/3, 01.05.2003, p. 311-332.

Research output: Contribution to journalArticle

Smith, SJ, Neugut, A, Heitjan, D, Forde, K, Holt, P, Santella, RM, Jiin-Chyuan, L, Carney, W, Ward, L & Brandt-Rauf, PW 2003, 'In situ quantification of aberrant p53 in colorectal neoplasia', Biomarkers, vol. 8 , no. 4/3, pp. 311-332. https://doi.org/10.1080/1354750031000138676
Smith SJ, Neugut A, Heitjan D, Forde K, Holt P, Santella RM et al. In situ quantification of aberrant p53 in colorectal neoplasia. Biomarkers. 2003 May 1;8 (4/3):311-332. https://doi.org/10.1080/1354750031000138676
Smith, Steven Jay ; Neugut, Alfred ; Heitjan, Daniel ; Forde, Kenneth ; Holt, Peter ; Santella, Regina M. ; Jiin-Chyuan, Luo ; Carney, Walter ; Ward, Llewelyn ; Brandt-Rauf, Paul W. / In situ quantification of aberrant p53 in colorectal neoplasia. In: Biomarkers. 2003 ; Vol. 8 , No. 4/3. pp. 311-332.
@article{53842ad14fa74364a6450d63e7e46ab5,
title = "In situ quantification of aberrant p53 in colorectal neoplasia",
abstract = "Aberrant p53 protein accumulation was measured immunohistologically in 342 colorectal paraffin-embedded tissue sections from 115 patients (24 with adenocarcinoma, 59 with adenoma and 32 'hospital controls'). Subjective scoring was compared with quantitative cell imaging, including dichotomous (p53+/p53-) status, ng p53mut mg-1 enterocyte protein, and tumour burden and patient body 'burden' of aberrant p53. A total of 62.5{\%} cancer patients, 23.7{\%} adenoma patients and 3.1{\%} hospital controls were accorded p53+ status on the basis of p53 quantification. Quantitative p53+/p53- assignment had a stronger inverse association with survival (χ2 = 6.17, p = 0.013, Kaplan-Meier test) than subjective 'visual estimation' (χ2 = 0.57, p = 0.449). There was a strong inverse relationship between the p53 'body burden' and the months of post-diagnosis survival (hazard ratio = 1.42, p = 0.0004, Cox proportional hazards). Absolute quantification for inactivated p53 permits objective and reproducible scoring, adjusts for intra-laboratory immunostaining 'batch effects', corrects for fixation artefacts, and standardizes for inter-laboratory differences in fixation, antibody selection and staining method. Clinically, in situ quantification of p53 will permit more accurate survival prognoses and will inform therapy selection and dose. Ultimately, accurate quantitative tissue/blood p53 correlations may provide a minimally invasive and systemic surrogate measure for these same clinical purposes.",
keywords = "Cell imaging densitometry, Colorectal, Immunohistochemistry, p53, Protein quantitation, Tumour/tumour tissue",
author = "Smith, {Steven Jay} and Alfred Neugut and Daniel Heitjan and Kenneth Forde and Peter Holt and Santella, {Regina M.} and Luo Jiin-Chyuan and Walter Carney and Llewelyn Ward and Brandt-Rauf, {Paul W.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1080/1354750031000138676",
language = "English (US)",
volume = "8",
pages = "311--332",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Informa Healthcare",
number = "4/3",

}

TY - JOUR

T1 - In situ quantification of aberrant p53 in colorectal neoplasia

AU - Smith, Steven Jay

AU - Neugut, Alfred

AU - Heitjan, Daniel

AU - Forde, Kenneth

AU - Holt, Peter

AU - Santella, Regina M.

AU - Jiin-Chyuan, Luo

AU - Carney, Walter

AU - Ward, Llewelyn

AU - Brandt-Rauf, Paul W.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Aberrant p53 protein accumulation was measured immunohistologically in 342 colorectal paraffin-embedded tissue sections from 115 patients (24 with adenocarcinoma, 59 with adenoma and 32 'hospital controls'). Subjective scoring was compared with quantitative cell imaging, including dichotomous (p53+/p53-) status, ng p53mut mg-1 enterocyte protein, and tumour burden and patient body 'burden' of aberrant p53. A total of 62.5% cancer patients, 23.7% adenoma patients and 3.1% hospital controls were accorded p53+ status on the basis of p53 quantification. Quantitative p53+/p53- assignment had a stronger inverse association with survival (χ2 = 6.17, p = 0.013, Kaplan-Meier test) than subjective 'visual estimation' (χ2 = 0.57, p = 0.449). There was a strong inverse relationship between the p53 'body burden' and the months of post-diagnosis survival (hazard ratio = 1.42, p = 0.0004, Cox proportional hazards). Absolute quantification for inactivated p53 permits objective and reproducible scoring, adjusts for intra-laboratory immunostaining 'batch effects', corrects for fixation artefacts, and standardizes for inter-laboratory differences in fixation, antibody selection and staining method. Clinically, in situ quantification of p53 will permit more accurate survival prognoses and will inform therapy selection and dose. Ultimately, accurate quantitative tissue/blood p53 correlations may provide a minimally invasive and systemic surrogate measure for these same clinical purposes.

AB - Aberrant p53 protein accumulation was measured immunohistologically in 342 colorectal paraffin-embedded tissue sections from 115 patients (24 with adenocarcinoma, 59 with adenoma and 32 'hospital controls'). Subjective scoring was compared with quantitative cell imaging, including dichotomous (p53+/p53-) status, ng p53mut mg-1 enterocyte protein, and tumour burden and patient body 'burden' of aberrant p53. A total of 62.5% cancer patients, 23.7% adenoma patients and 3.1% hospital controls were accorded p53+ status on the basis of p53 quantification. Quantitative p53+/p53- assignment had a stronger inverse association with survival (χ2 = 6.17, p = 0.013, Kaplan-Meier test) than subjective 'visual estimation' (χ2 = 0.57, p = 0.449). There was a strong inverse relationship between the p53 'body burden' and the months of post-diagnosis survival (hazard ratio = 1.42, p = 0.0004, Cox proportional hazards). Absolute quantification for inactivated p53 permits objective and reproducible scoring, adjusts for intra-laboratory immunostaining 'batch effects', corrects for fixation artefacts, and standardizes for inter-laboratory differences in fixation, antibody selection and staining method. Clinically, in situ quantification of p53 will permit more accurate survival prognoses and will inform therapy selection and dose. Ultimately, accurate quantitative tissue/blood p53 correlations may provide a minimally invasive and systemic surrogate measure for these same clinical purposes.

KW - Cell imaging densitometry

KW - Colorectal

KW - Immunohistochemistry

KW - p53

KW - Protein quantitation

KW - Tumour/tumour tissue

UR - http://www.scopus.com/inward/record.url?scp=12444262322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444262322&partnerID=8YFLogxK

U2 - 10.1080/1354750031000138676

DO - 10.1080/1354750031000138676

M3 - Article

VL - 8

SP - 311

EP - 332

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 4/3

ER -